de Miguel, D
Lemke, J
Anel, A
Walczak, H
Martinez-Lostao, L
Article History
Received: 21 August 2015
Revised: 11 December 2015
Accepted: 17 December 2015
First Online: 4 March 2016
Competing interests
: AA and LM-L have filed a patent application (W02011020933) for the use of liposome-bound Apo2L/TRAIL. HW is a co-founder and shareholder of Apogenix GmbH, Heidelberg, Germany, and a named inventor on the patent that underlies the development of the TRAIL-R2-specific antibody Conatumumab. The remaining authors declare no conflict of interest.